Lisata Therapeutics Acquired by Kuva Labs for $4/Share
Kuva Labs to acquire Lisata at $4/share plus $2 in contingent payments—an 85% premium. Deal expected to close before Feb 27, 2026.
/ 678 items
#Healthcare↓
BofA Starts Coverage of Inhibikase Therapeutics with Buy Rating
BofA gives Inhibikase Therapeutics (IKT) a Buy rating with $6 target, citing strong data, regulatory support, and promising leukemia therapy for PAH.
RBC Capital Turns Bullish on Biohaven: Big Upgrade and Higher Price Target
RBC Capital upgrades Biohaven to Outperform, raises price target to $22, and highlights improving data, lower risk, and strong 2026 catalysts.
BofA Upgrades Apellis as Empaveli Shows Strong Early Momentum
Bank of America upgraded Apellis to Buy, citing undervalued shares and strong early uptake of Empaveli in rare kidney diseases.
FDA Signals Faster Drug Approvals for Multiple Myeloma — Positive Read for Legend Biotech
FDA draft guidance supports new approval endpoints in multiple myeloma, potentially speeding drug development and boosting prospects for Legend Biotech’s CARTITUDE-6.
Qiagen Considers Sale as Takeover Interest Returns
Qiagen is reviewing strategic options, including a possible sale, as takeover interest resurfaces in the fast-growing life sciences and diagnostics sector.